SNP-830

**SNP-830** is a preclinical prescription fixed-dose analgesic combination developed by Sinew Pharma for moderate to severe pain. Sinew describes SNP-830 and the related SNP-840 jointly as combinations of its hepatotoxicity-reduced acetaminophen product SNP-810 with different opioid analgesics, stated to be oxycodone or hydrocodone. The intended mechanism is to inhibit hepatic enzyme activity implicated in formation of toxic acetaminophen metabolites, thereby improving liver safety while preserving synergistic opioid-containing analgesia. The sponsor has not publicly specified which opioid or exact formulation belongs specifically to SNP-830 rather than SNP-840. ([sinewpharma.com](https://www.sinewpharma.com/en/products-detail3-6.htm))